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Introduction {#sec005}
============

Systemic lupus erythematosus (SLE) is a chronic, systemic, relapsing-remitting autoimmune disease of unknown etiology with heterogeneous manifestations, including diverse neuropsychiatric (NP) manifestations \[[@pone.0144149.ref001]\]. Neurologic and psychiatric syndromes, collectively referred to as neuropsychiatric systemic lupus erythematosus (NPSLE), occur frequently in patients with SLE \[[@pone.0144149.ref002]\]. Approximately one-third of NP events are directly attributable to SLE, although the attribution rates vary between individual manifestations \[[@pone.0144149.ref002]\]. Over the past few decades, as the longevity of SLE patients has increased, NPSLE has been identified as one of the important factors negatively affecting of survival of SLE patients over the past 50 years \[[@pone.0144149.ref001], [@pone.0144149.ref003]\]. Among the 19 NPSLE syndromes identified by the American College of Rheumatology (ACR) Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature, cognitive dysfunction is the most prevalent manifestation of NPSLE and has been reported in up to 20--80% of SLE patients \[[@pone.0144149.ref003], [@pone.0144149.ref004]\]. The variability in the frequency of cognitive dysfunction is due to several factors, including bias in selection of patients for study and operational decisions regarding the definition of cognitive dysfunction \[[@pone.0144149.ref005]\]. Cognitive impairment scores as an item in the Systemic Lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index \[[@pone.0144149.ref006]\]. Accrual of such damage from cognitive dysfunction translates to increased negative impact on health-related quality of life and unemployment rates \[[@pone.0144149.ref007], [@pone.0144149.ref008]\].

Identifying nutritional factors that may mitigate cognitive dysfunction and help preserve higher-level cognitive abilities has significant economic and public health benefits \[[@pone.0144149.ref009]\]. Epidemiological studies within the general population have demonstrated that vitamin D deficiency is a potential risk factor for cognitive impairment \[[@pone.0144149.ref010], [@pone.0144149.ref011]\]. It has also become recently apparent that vitamin D deficiency contributes to the disease activity and morbidity of SLE \[[@pone.0144149.ref012]\]. Vitamin D is available in 2 distinct forms, vitamin D~2~ (ergocalciferol) and vitamin D~3~ (cholecalciferol) \[[@pone.0144149.ref013]\]. The 2011 Institute of Medicine report concluded that serum 25(OH)D is the most useful marker for vitamin D nutriture, without distinguishing between 25(OH)D~2~ and 25(OH)D~3~ forms \[[@pone.0144149.ref014]\]. However, as vitamin D~3~ is more effective than vitamin D~2~ in raising 25(OH)D concentrations and experimental evidence has revealed that binding of 1,25(OH)~2~D~3~ to its cognate nuclear vitamin D receptor (VDR) represents an important molecular event, we hypothesize that measurement of 25(OH)D~3~ represents a more accurate estimation of *in vivo* vitamin D status and may thus affect cognitive function in SLE patients \[[@pone.0144149.ref013]\]. To our knowledge, the relationship between vitamin D and cognitive function in patients with SLE has never been addressed. We undertook this study to evaluate the relationship between 25(OH)D~3~, traditional neuropsychological and SLE-specific risk factors and cognitive dysfunction in a multiethnic Asian population living close to the equator.

Patients and Methods {#sec006}
====================

Subjects {#sec007}
--------

Adult SLE patients attending the outpatient clinics of National University Hospital (NUH), Singapore, between 2011 and 2014 who fulfilled at least 4 of the ACR 1997 revised classification criteria were invited to participate in this study \[[@pone.0144149.ref015]\]. Objectively documented cognitive dysfunction or other NP events were not required for inclusion. Exclusion criteria included the following: (i) patients with known intellectual disability or previous stroke with resultant neuromuscular dysfunction; (ii) subjects who were pregnant; (iii) subjects less than 21 years of age and (iv) subjects who had active infections at the time of recruitment. Community-derived healthy controls (HCs) were recruited using poster advertisement in the hospital or were the nursing staff of NUH. The HCs were selected for the absence of any acute or chronic psychiatric, neurologic or medical conditions. Those who required medications which could alter cognitive function were excluded. All subjects had completed at least primary school education with adequate English fluency. The study was approved by NHG Domain Specific Review Board E (reference code: 2011/01764) and was carried out in accordance with the principles of the Declaration of Helsinki. All subjects gave written informed consent prior to study inclusion.

Study design {#sec008}
------------

The study was cross-sectional in design. Consecutive SLE patients and community-derived HCs matched by age (± 5years) and gender were recruited.

SLE-related disease characteristics {#sec009}
-----------------------------------

Demographic and relevant clinical data were extracted from the medical records of SLE patients. NP events were compiled by the study rheumatologists (S.H. Tay and A. Mak). Global SLE disease activity and SLE-related disease damage were assessed using the Safety of Estrogens in Lupus Erythematosus National Assessment (SELENA)-modified SLE Disease Activity Index (SLEDAI) and the SLICC/ACR Damage Index, respectively \[[@pone.0144149.ref006], [@pone.0144149.ref016]\].

Psychopathology questionnaire {#sec010}
-----------------------------

The Hospital Anxiety and Depression Scale (HADS) was used to assess self-reported symptoms of anxiety and depression. It is a 14-item multiple-choice questionnaire which comprises two 7-item subscales for measuring anxiety (HADS-Anxiety) and depression (HADS-Depression). Scores range from 0--21 for each subscale. A cut-off score of ≥ 8 on either subscale is used to define clinical anxiety and depression \[[@pone.0144149.ref017]\]. Summing scores across both subscales generates a total psychopathology score (HADS-Total).

Neuropsychological test and definition of cognitive dysfunction {#sec011}
---------------------------------------------------------------

Cognitive function was evaluated using Automated Neuropsychological Assessment Metrics (ANAM), version 4.3 (Vista LifeSciences Inc, Denver, CO, US). The ANAM is a self-administered computer battery of tests to assess neurocognitive efficiency and it is less sensitive to confounding effects of education, English language proficiency and ethnic differences than traditional neuropsychological testing \[[@pone.0144149.ref018]\]. ANAM tests selected for this study included simple reaction time (neuromuscular response efficiency, 40 trials) and 8 tests: (i) code substitution-learning (learning and recall, 72 trials); (ii) code substitution-immediate (learning and recall, 36 trials); (iii) code substitution-delayed (learning and recall, 36 trials); (iv) spatial processing (visual perception and mental rotation, 20 trials); (v) matching to sample (short-term memory, attention and visual-spatial discrimination, 20 trials); (vi) running memory continuous performance test (CPT) (sustained attention, 80 trials); (vii) mathematical processing (working memory, 20 trials) and (viii) memory search (working memory, 40 trials). Each ANAM test generates a "throughput" (TP) measure, which is sensitive to cognitive performance, incorporates speed and accuracy in one variable and more closely conforms to a normal distribution than other ANAM measures \[[@pone.0144149.ref019]\]. The primary outcome of our study was the total throughput score (TTS), which is the total of the throughput scores for each of the 8 ANAM tests \[[@pone.0144149.ref020]\]. Cognitive dysfunction was defined as TTS \< 1.5 SD below the mean of the HCs \[[@pone.0144149.ref020]\].

Assay of 25(OH)D~3~ and definition of vitamin D deficiency {#sec012}
----------------------------------------------------------

Quantitative determination of serum 25(OH)D~3~ was performed at an external laboratory (Prince of Wales Hospital, Hong Kong SAR, China) using liquid chromatography-tandem mass spectrometry (LC-MS/MS) as the candidate reference method to measure both 25(OH)D~3~ and total 25(OH)D \[25(OH)D~2~ + 25(OH)D~3~\] \[[@pone.0144149.ref021]\]. Processed serum was stored at -80°C until retrieval for analyses. Total 25(OH)D was also measured using the Roche Elecsys vitamin D total assay immediately after collection at the local laboratory of NUH. Vitamin D status was operationally defined as deficiency \< 10 ng/mL, insufficient 10--29 ng/mL and sufficient ≥ 30 ng/mL as per the clinical laboratory reference ranges of NUH.

Study procedures {#sec013}
----------------

For each subject, HADS, ANAM, and if applicable, SELENA-SLEDAI and SLICC/ACR Damage Index were assessed on the day when serum samples were collected.

Statistical methods {#sec014}
-------------------

As most of the published normative data are for young men (because ANAM was developed by the US Department of Defense) and since SLE patients could not be their own controls in a cross-sectional study; therefore, a control group was required to assess (i) prevalence of cognitive dysfunction and (ii) the association of vitamin D deficiency with cognitive impairment in SLE patients \[[@pone.0144149.ref022], [@pone.0144149.ref023]\]. 25(OH)D~3~ and total 25(OH)D levels were examined as continuous variables and also as deficient, insufficient and sufficient categorical variables. Multiple linear regression was used to identify independent predictors for TTS and to test for group differences in the TTS while adjusting for potential confounders. In all models, we controlled for baseline confounders including age, education, gender, ethnicity and HADS-Total. In the fully adjusted model, we adjusted for SLE-specific variables that have been identified as potential confounders in studies of cognition: duration of SLE, SELENA-SLEDAI, SLICC/ACR Damage Index and cumulative steroid dose. To ascertain the validity of the regression equations, only independent variables of tolerance \> 0.4 were accepted into the final regression model. Statistical significance was defined as a two-tailed p value of \< 0.05. All statistical analyses were performed with SPSS, version 23.0 (IBM Corp, Armonk, NY, US).

Results {#sec015}
=======

Characteristics of SLE patients and healthy controls {#sec016}
----------------------------------------------------

In total, 61 SLE patients and 61 HCs were studied. The SLE patients and HCs were comparable in terms of age, gender and body mass index ([Table 1](#pone.0144149.t001){ref-type="table"}). However, there were statistically significant differences in ethnicity and duration of education \[SLE patients: 12.0 years (Q1; Q3 10.0; 15.0) versus HCs: 16.0 years (Q1; Q3 14.0; 18.0), p \< 0.001\]. SLE patients had the following characteristics: 83.6% female; median age 36.0 (Q1; Q3 26.0; 48.5); SLE duration 6.0 years (Q1; Q3 0.0; 12.0); SELENA-SLEDAI 4.0 (Q1; Q3 2.0; 5.0) and SLICC/ACR Damage Index 0.0 (Q1; Q3 0.0; 1.0) (Tables [1](#pone.0144149.t001){ref-type="table"} and [2](#pone.0144149.t002){ref-type="table"}). Fifty-six (91.8%) of the 61 SLE patients were taking prednisolone \[median dosage 7.5 mg/day (Q1; Q3 4.5; 16.3)\] with a cumulative prednisolone dose of 15.9 gm (Q1; Q3 7.4; 26.9) ([Table 2](#pone.0144149.t002){ref-type="table"}). Twelve (19.7%) of the 61 SLE patients had at least 1 NP event but no patient had documented cognitive dysfunction ([Table 2](#pone.0144149.t002){ref-type="table"}). Psychopathology parameters which included HADS-Anxiety, HADS-Depression and HADS-Total were significantly higher in SLE patients than those of HCs \[HADS-Anxiety: 8.0 (Q1; Q3 4.5; 9.0) versus 5.0 (Q1; Q3 2.5; 8.0), p = 0.001; HADS-Depression: 3.0 (Q1; Q3 2.0; 6.0) versus 2.0 (Q1; Q3 1.0; 3.0), p \< 0.001; HADS-Total: 11.0 (Q1; Q3 7.5; 15.0) versus 7.0 (Q1; Q3 3.0; 10.5), p \< 0.001\] ([Table 1](#pone.0144149.t001){ref-type="table"}). Significantly more SLE patients had clinical anxiety (50.8% versus 26.2%, p = 0.005) and depression (14.8% versus 1.6%, p = 0.008) than HCs ([Table 1](#pone.0144149.t001){ref-type="table"}).

10.1371/journal.pone.0144149.t001

###### Demographics, clinical and psychological characteristics of SLE patients versus healthy controls.

Data are no./no. assessed (%) or median (interquartile range).

![](pone.0144149.t001){#pone.0144149.t001g}

                                                                    SLE patients, n = 61   Healthy controls, n = 61   p
  ----------------------------------------------------------------- ---------------------- -------------------------- -------
  Age (years)                                                       36.0 (26.0--48.5)      29.0 (25.0--40.5)          0.091
  Gender (female)                                                   51 (83.6)              51 (83.6)                  1.000
  Ethnicity                                                                                                           0.000
  Chinese                                                           33 (54.1)              49 (80.3)                  
  Malay                                                             16 (26.2)              2 (3.3)                    
  Indian                                                            8 (13.1)               1 (1.6)                    
  Others[\*](#t001fn001){ref-type="table-fn"}                       4 (6.6)                9 (14.8)                   
  Education (years)                                                 12.0 (10.0--15.0)      16.0 (14.0--18.0)          0.000
  Body mass index (kg/m^2^)                                         23.0 (18.9--26.0)      22.3 (19.7--25.2)          0.834
  Menopause                                                         12/51 (23.5)           5/51 (9.8)                 0.062
  Current smoking                                                   7 (11.5)               1 (1.6)                    0.025
  Diabetes mellitus                                                 2 (3.3)                2 (3.3)                    1.000
  Hypertension                                                      22 (36.1)              2 (3.3)                    0.000
  Hypercholesterolemia                                              19 (31.1)              7 (11.5)                   0.008
  LDL cholesterol (mmol/L)                                          2.45 (2.14--2.94)      2.77 (2.41--3.35)          0.056
  HDL cholesterol (mmol/L)                                          1.43 (1.04--1.69)      1.54 (1.34--1.98)          0.065
  Total cholesterol (mmol/L)                                        4.63 (4.00--5.25)      4.87 (4.33--5.35)          0.188
  Triglyceride level (mmol/L)                                       1.12 (0.79--1.58)      0.83 (0.65--1.15)          0.015
  Total/HDL cholesterol ratio                                       3.29 (2.52--4.51)      3.00 (2.48--3.64)          0.129
  History of cardiovascular disease                                 9 (14.8)               0 (0.0)                    0.002
  History of stroke[\*\*](#t001fn002){ref-type="table-fn"}          4 (6.6)                0 (0.0)                    0.040
  History of myocardial infarction                                  4 (6.6)                0 (0.0)                    0.040
  Total 25(OH)D (ng/mL)[^†^](#t001fn003){ref-type="table-fn"}       22.7 (16.1--30.6)      19.7 (15.0--25.8)          0.112
  Total 25(OH)D (ng/mL)[^††^](#t001fn004){ref-type="table-fn"}      22.8 (17.6--29.0)      19.6 (16.0--24.8)          0.078
  25(OH)D~3~ (ng/mL)[^††^](#t001fn004){ref-type="table-fn"}         20.0 (12.0--24.8)      19.6 (16.0--24.8)          0.456
  Vitamin D~2~ or D~3~ supplementation                              57 (93.4)              12 (19.7)                  0.000
  Vitamin D~2~ supplementation                                      8 (13.1)               0 (0.0)                    0.000
  Total 25(OH)D deficiency[^††^](#t001fn004){ref-type="table-fn"}   5 (8.2)                2 (3.3)                    0.224
  25(OH)D~3~ deficiency[^††^](#t001fn004){ref-type="table-fn"}      12 (19.7)              2 (3.3)                    0.003
  HADS-Total                                                        11.0 (7.5--15.0)       7.0 (3.0--10.5)            0.000
  HADS-Anxiety (0--21)                                              8.0 (4.5--9.0)         5.0 (2.5--8.0)             0.001
  Anxiety                                                                                                             0.005
  ≥8                                                                31 (50.8)              16 (26.2)                  
  \<8                                                               30 (49.2)              45 (73.8)                  
  HADS-Depression (0--21)                                           3.0 (2.0--6.0)         2.0 (1.0--3.0)             0.000
  Depression                                                                                                          0.008
  ≥8                                                                9 (14.8)               1 (1.6)                    
  \<8                                                               52 (85.2)              60 (98.4)                  

\* All were Burmese or Filipinos

\*\* All 4 SLE patients with stroke did not have impaired mobility

† Measured using Roche Elecsys vitamin D total assay

^††^ Measured using LC--MS/MS.

10.1371/journal.pone.0144149.t002

###### Cumulative clinical features of SLE patients at time of study recruitment.

Data are no./no. assessed (%) or median (interquartile range).

![](pone.0144149.t002){#pone.0144149.t002g}

  --------------------------------------------- --------------------
  Age at diagnosis of SLE (years)               28.0 (19.0--36.0)
  Duration of SLE (years)                       6.0 (0.0--12.0)
  SELENA-SLEDAI                                 4.0 (2.0--5.0)
  SLICC/ACR Damage Index                        0.0 (0.0--1.0)
  Positive anti-dsDNA                           31 (50.8)
  Anti-dsDNA (IU)                               42.0 (11.0--188.5)
  Low C3                                        31 (50.8)
  Low C4                                        19 (31.1)
  Positive antiphospholipid antibodies          20 (32.8)
  Positive lupus anticoagulant                  9 (14.8)
  ACR classification criteria                   
  Malar rash                                    21 (34.4)
  Discoid rash                                  4 (6.6)
  Photosensitivity                              14 (23.0)
  Oral ulcers                                   11 (18.0)
  Arthritis                                     38 (62.3)
  Serositis                                     19 (31.1)
  Renal disorder                                28 (45.9)
  Neurologic disorder (seizures or psychosis)   4 (6.6)
  Hematologic disorder                          56 (91.8)
  Immunologic disorder                          54 (88.5)
  ANA positivity                                54 (88.5)
  NPSLE syndromes                               12 (19.7)
  Aseptic meningitis                            2 (3.3)
  Headache                                      1 (1.6)
  Myelopathy                                    1 (1.6)
  Seizure disorders                             4 (6.6)
  Psychosis                                     1 (1.6)
  Cranial neuropathy                            1 (1.6)
  Polyneuropathy                                2 (3.3)
  Medications                                   
  Prednisolone                                  56 (91.8)
  Prednisolone dose (mg/day)                    7.5 (4.5--16.3)
  Number of IV methylprednisolone pulse         2.0 (0.0--5.0)
  Cumulative prednisolone dose (gm)             15.9 (7.4--26.9)
  Hydroxychloroquine                            58 (95.1)
  Warfarin                                      7 (11.5)
  Antidepressants                               2 (3.3)
  Anticonvulsants                               0 (0.0)
  Statins                                       17 (27.9)
  Azathioprine                                  16 (26.2)
  Mycophenolate mofetil                         17 (27.9)
  Calcineurin inhibitors                        7 (11.5)
  Cyclophosphamide                              7 (11.5)
  --------------------------------------------- --------------------

Vitamin D levels and status {#sec017}
---------------------------

The levels and status of vitamin D in patients with SLE and HCs are shown in [Table 1](#pone.0144149.t001){ref-type="table"}. SLE patients were more likely than HCs to use any vitamin D supplements (93.4% versus 19.7%, p \< 0.001), particularly vitamin D~2~ supplements (13.1% versus 0.0%, p \< 0.001). Total 25(OH)D levels were similar using LC-MS/MS and Roche Elecsys vitamin D total assay methods and did not differ between SLE patients and HCs. There was no significant difference in 25(OH)D~3~ levels between SLE patients and HCs. The prevalence of total 25(OH)D deficiency was similar in SLE patients and HCs (8.2% versus 3.3%, p = 0.224). However, significantly more SLE patients than HCs had 25(OH)D~3~ deficiency (19.7% versus 3.3%, p = 0.003).

Group differences in performance on ANAM testing {#sec018}
------------------------------------------------

Throughput scores for each of the ANAM tests and TTS for SLE patients and HCs are summarized in [Table 3](#pone.0144149.t003){ref-type="table"}. After adjusting for age, education, gender, ethnicity and HADS-Total, SLE patients scored significantly lower than HCs in 4 of the ANAM tests (code substitution-learning, p = 0.013; code substitution-immediate, p = 0.012; code substitution-delayed, p = 0.025; matching to sample, p = 0.026) and in the TTS (p = 0.004) ([Fig 1](#pone.0144149.g001){ref-type="fig"}). Simple reaction time and running memory CPT did not differ significantly between both groups. Twenty-one (34.4%) of the 61 SLE patients were identified as having cognitive dysfunction by ANAM in comparison with 1 (1.6%) of 61 HCs (p \< 0.001).

![Mean throughput scores in SLE patients and HCs.\
Higher scores represent better performance. The individual test data points for each group are connected for illustration purposes only. \*P\<0.05; \*\*P\<0.01.](pone.0144149.g001){#pone.0144149.g001}

10.1371/journal.pone.0144149.t003

###### Comparison of ANAM throughput scores for SLE patients and healthy controls.

Data are no./no. assessed (%) or mean (standard deviation).
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  ANAM measure                                                   SLE patients, n = 61   Healthy controls, n = 61   p       p[\*](#t003fn001){ref-type="table-fn"}
  -------------------------------------------------------------- ---------------------- -------------------------- ------- ----------------------------------------
  Simple reaction time                                           179.18 ± 43.09         203.21 ± 34.52             0.001   0.565
  Code substitution (learning)                                   43.61 ± 11.59          52.22 ± 13.30              0.000   0.013
  Code substitution (immediate memory)                           34.95 ± 16.87          46.73 ± 17.15              0.000   0.012
  Code substitution (delayed memory)                             39.10 ± 18.72          50.61 ± 16.87              0.000   0.025
  Spatial processing                                             22.92 ± 7.27           27.16 ± 6.49               0.001   0.098
  Matching to sample                                             26.72 ± 13.89          35.80 ± 13.14              0.000   0.026
  Running memory CPT                                             75.78 ± 24.66          89.70 ± 14.24              0.000   0.050
  Mathematical processing                                        21.07 ± 7.56           26.50 ± 6.52               0.000   0.087
  Memory search                                                  58.04 ± 17.46          67.14 ± 16.70              0.004   0.108
  Total throughput                                               322.18 ± 100.86        395.86 ± 83.26             0.000   0.004
  Cognitive dysfunction[\*\*](#t003fn002){ref-type="table-fn"}   21 (34.4)              1 (1.6)                    0.000   

\* Adjusted for age, education, gender, ethnicity and HADS-Total

\*\* Cognitive dysfunction definition: A cut-off for cognitive dysfunction was defined as a total throughput score below -1.5 SD of the health controls mean.

Vitamin D deficiency and cognitive function {#sec019}
-------------------------------------------

Multiple linear regression models were constructed for all subjects, and for HCs and SLE patients which were analyzed separately (Tables [4](#pone.0144149.t004){ref-type="table"}, [5](#pone.0144149.t005){ref-type="table"} and [6](#pone.0144149.t006){ref-type="table"}). Age and SLE status were negative predictors for cognitive function in the regression model for all subjects, and age (β = -4.261, SE = 0.866, p \< 0.001) was the only predictor for cognitive function in the HC group. Deficiency of 25(OH)D~3~, but not other vitamin D variables, independently predicted worse cognitive function in the final regression models for all subjects (β = -46.977, SE = 21.949, p = 0.035) and SLE patients (β = -63.667, SE = 27.456, p = 0.025). Mean TTS varied significantly by 25(OH)D~3~ status in SLE patients (one-way ANOVA, F(2,52) = 3.73, p = 0.031) ([Fig 2](#pone.0144149.g002){ref-type="fig"}). Chinese ethnicity was significantly associated with higher TTS in the SLE group. Age, education, HADS-Total and 25(OH)D~3~ levels did not differ significantly amongst the different ethnicities in the SLE group (one-way ANOVA, p \> 0.05). The study sample was also analyzed for potential associations between cognitive performance and other clinical characteristics. There was no significant association between SLE patients with cognitive dysfunction and anti-dsDNA levels, stroke or antiphospholipid antibodies. Levels of 25(OH)D~3~ correlated negatively with the SLICC/ACR Damage Index (r = -0.326, p = 0.015) but not with the SELENA-SLEDAI.

![Total throughput scores in relation to 25(OH)D~3~ status in SLE patients.\
Box represents 25^th^ and 75^th^ percentiles, horizontal line represents the median, error bars show the 5^th^ and 95^th^ percentile and outside values are shown as dots. F(2,52) = 3.73, p = 0.031.](pone.0144149.g002){#pone.0144149.g002}

10.1371/journal.pone.0144149.t004

###### Results of multiple linear regression analysis between total throughput score and demographic, neuropsychological and clinical variables for 61 SLE patients and 61 healthy controls.
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                                                     Independent variable         β (SE)             Beta     P       R^2^
  -------------------------------------------------- ---------------------------- ------------------ -------- ------- -------
  Model 1[\*](#t004fn001){ref-type="table-fn"}                                                                        0.471
                                                     Age                          -4.523 (0.586)     -0.518   0.00    
                                                     Chinese                      59.977 (14.509)    0.285    0.00    
                                                     SLE status (yes versus no)   -40.673 (13.778)   -0.206   0.04    
  Model 2[\*\*](#t004fn002){ref-type="table-fn"}                                                                      0.441
                                                     Age                          -4.495 (0.619)     -0.516   0.000   
                                                     Chinese                      58.515 (15.621)    0.274    0.000   
                                                     SLE status (yes versus no)   -40.399 (14.579)   -0.205   0.007   
  Model 3[\*\*\*](#t004fn003){ref-type="table-fn"}                                                                    0.459
                                                     Age                          -4.422 (0.611)     -0.508   0.000   
                                                     Chinese                      53.511 (15.550)    0.250    0.001   
                                                     SLE status (yes versus no)   -33.242 (14.732)   -0.168   0.026   
                                                     25(OH)D~3~ deficiency        -46.977 (21.949)   -0.156   0.035   

\* Model included age, education, gender, ethnicity, HADS-Total and SLE status; significant variables reported.

\*\* Model included age, education, gender, ethnicity, HADS-Total, SLE status and 25(OH)D~3~; significant variables reported.

\*\*\* Model included age, education, gender, ethnicity, HADS-Total, SLE status and 25(OH)D~3~ status; significant variables reported.

10.1371/journal.pone.0144149.t005

###### Results of multiple linear regression analysis between total throughput score and demographic, neuropsychological and clinical variables for 61 healthy controls.
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                                                     Independent variable   β (SE)           Beta     P       R^2^
  -------------------------------------------------- ---------------------- ---------------- -------- ------- -------
  Model 1[\*](#t005fn001){ref-type="table-fn"}                                                                0.300
                                                     Age                    -4.380 (0.848)   -0.558   0.00    
  Model 2[\*\*](#t005fn002){ref-type="table-fn"}                                                              0.286
                                                     Age                    -4.261 (0.866)   -0.546   0.000   
  Model 3[\*\*\*](#t005fn003){ref-type="table-fn"}                                                            0.286
                                                     Age                    -4.261 (0.866)   -0.546   0.000   

\* Model included age, education, gender, ethnicity and HADS-Total; significant variable reported.

\*\* Model included age, education, gender, ethnicity, HADS-Total and 25(OH)D~3~; significant variable reported.

\*\*\* Model included age, education, gender, ethnicity, HADS-Total and 25(OH)D~3~ status; significant variable reported.

10.1371/journal.pone.0144149.t006

###### Results of multiple linear regression analysis between total throughput score and demographic, neuropsychological and clinical variables for 61 SLE patients.
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                                                       Independent variable    β (SE)             Beta     P       R^2^
  ---------------------------------------------------- ----------------------- ------------------ -------- ------- -------
  Model 1[\*](#t006fn001){ref-type="table-fn"}                                                                     0.452
                                                       Age                     -4.652 (0.812)     -0.548   0.000   
                                                       Chinese                 78.687 (19.200)    0.392    0.000   
  Model 2[\*\*](#t006fn002){ref-type="table-fn"}                                                                   0.420
                                                       Age                     -4.654 (0.889)     -0.543   0.000   
                                                       Chinese                 77.817 (21.248)    0.380    0.001   
  Model 3[\*\*\*](#t006fn003){ref-type="table-fn"}                                                                 0.462
                                                       Age                     -4.421 (0.862)     -0.516   0.000   
                                                       Chinese                 70.472 (20.712)    0.344    0.001   
                                                       25(OH)D~3~ deficiency   -56.605 (25.047)   -0.230   0.028   
  Model 4[\*\*\*\*](#t006fn004){ref-type="table-fn"}                                                               0.458
                                                       Age                     -4.205 (0.973)     -0.470   0.000   
                                                       Chinese                 80.290 (22.863)    0.379    0.001   
                                                       25(OH)D~3~ deficiency   -63.667 (27.456)   -0.253   0.025   

\* Model included age, education, gender, ethnicity and HADS-Total; significant variables reported.

\*\* Model included age, education, gender, ethnicity, HADS-Total and 25(OH)D~3~; significant variables reported.

\*\*\* Model included age, education, gender, ethnicity, HADS-Total and 25(OH)D~3~ status; significant variables reported.

\*\*\*\* Model included age, education, gender, ethnicity, HADS-Total, 25(OH)D~3~ status, duration of SLE, SELENA-SLEDAI, SLICC/ACR Damage Index and cumulative steroid dose; significant variables reported.

Discussion {#sec020}
==========

The current study demonstrated that 25(OH)D~3~ deficiency independently predicted worse cognitive function, irrespective of the measured potential confounders. The association between cognitive function and 25(OH)D~3~ but not with total 25(OH)D is in accordance with our hypothesis that 25(OH)D~3~ represents a more accurate estimation of *in vivo* vitamin D status to affect cognitive function. Our study also confirmed that SLE patients had poorer cognitive performance on ANAM assessment compared to HCs \[[@pone.0144149.ref005], [@pone.0144149.ref022]\]. Some notable points of our study include: (i) SLE patients in the current study were not selected based on the presence and absence of NP manifestations; (ii) SLE patients had mild disease activity and disease-related damage and (iii) the absence of difference between groups in simple reaction time and running memory CPT mitigated differential effects on fatigue and inattentiveness on ANAM performance between the two groups. Thus, the inferior cognitive performance amongst the SLE patients compared to HCs in this study sample is particularly striking. While a single pattern of SLE-attributed cognitive dysfunction has not been found, commonly reported cognitive domains which are abnormal in patients with SLE include overall cognitive slowing, decreased attention, executive dysfunction and impaired working memory to suggest subcortical brain involvement reminiscent of white matter dementias; whereas, vitamin D has been associated with associated with several beneficial measures on cognitive domains associated with subcortical function, such as processing speed, attention and executive function \[[@pone.0144149.ref003], [@pone.0144149.ref009], [@pone.0144149.ref024]\].

Recent evidence has suggested a link between low vitamin D levels and impaired brain functioning. 25(OH)D~3~ crosses the blood-brain barrier to reach VDRs which are present on neurons and glial cells of the central nervous system (CNS), often co-localized in cells expressing 1α-hydroxylase \[[@pone.0144149.ref025], [@pone.0144149.ref026]\]. There is conversion of 25(OH)D~3~ to the biologically active 1,25(OH)~2~D~3~ in the CNS, qualifying vitamin D as a neurosteroid \[[@pone.0144149.ref027], [@pone.0144149.ref028]\]. The physiological properties of neurosteroids are diverse and differ temporally and regionally within the brain \[[@pone.0144149.ref027]\]. In line with this, neonatal rats exposed to vitamin D deficiency during brain development show changes in brain structure and neurochemistry \[[@pone.0144149.ref029]\]. 1,25(OH)~2~D~3~ has effects on neurotrophic function, neuroprotection and neuroimmunomodulation *in vitro* \[[@pone.0144149.ref010], [@pone.0144149.ref030]\]. 1,25(OH)~2~D~3~ upregulates synthesis of nerve growth factor, neurotropin 3 and low-affinity p75~NTR~ receptors \[[@pone.0144149.ref010], [@pone.0144149.ref030]\]. It regulates the intra-neuronal calcium homeostasis via voltage-gated calcium channels and exhibits neuroprotective properties against glutamate toxicity through antioxidant effects \[[@pone.0144149.ref030], [@pone.0144149.ref031]\]. Lastly, 1,25(OH)~2~D~3~ inhibits the expression of major histocompatibility complex class II proteins and sensitizes inflammatory cells to apoptotic signals \[[@pone.0144149.ref010], [@pone.0144149.ref030]\]. Functionally, the substantial expression of VDRs in the cortex and hippocampus suggests a potentially significant impact of 25(OH)D~3~ on cognition \[[@pone.0144149.ref032]\]. Therefore, these observations support the pharmacological potential of 25(OH)D~3~ in neuroimmunological and neurodegenerative disease management strategies \[[@pone.0144149.ref030]\]. Two recent meta-analyses of observational studies have concluded the potential positive effects of vitamin D in cognitive function \[[@pone.0144149.ref010], [@pone.0144149.ref011]\]. Herein, we argue that the use of vitamin D~2~ in some of the earlier studies to be study weaknesses as vitamin D~2~ administration may lead to reduction of 25(OH)D~3~ \[[@pone.0144149.ref033]\].

Vitamin D has a spectrum of immunoregulatory actions, many of which have been found to oppose the observed immunological aberrations in SLE \[[@pone.0144149.ref034], [@pone.0144149.ref035]\]. VDRs are expressed on immune cells of the innate and adaptive immune systems, including monocytes, macrophages,dendritic cells and lymphocytes \[[@pone.0144149.ref036]\]. These immune cells express 1α-hydroxylase to convert vitamin D to its biologically active form, 1,25(OH)~2~D~3~, for paracrine or autocrine signaling in the local immunologic milieu \[[@pone.0144149.ref036], [@pone.0144149.ref037]\]. 1,25(OH)~2~D~3~ binds to the VDR which acts as a transcription factor to determine a genomic response that regulates the transcription of 229 genes \[[@pone.0144149.ref038]\]. These VDR binding sites are significantly enriched near autoimmune genes identified from genome-wide association studies \[[@pone.0144149.ref038]\]. 1,25(OH)~2~D~3~ promotes chemotaxis and phagocytosis of macrophages which are important for the clearance of apoptotic cells \[[@pone.0144149.ref034]\]. 1,25(OH)~2~D~3~ potently inhibits type I IFN-mediated pathway of monocyte differentiation into dendritic cells \[[@pone.0144149.ref039]\]. By modulating the activation, maturation and survival of dendritic cells, 1,25(OH)~2~D~3~ affects the phenotype and function of interacting T cells by skewing the T cell compartment to a more anti-inflammatory and regulatory state, leading to the inhibition of Th1 and Th17 cells and induction of Th2, natural killer T and T regulatory cells \[[@pone.0144149.ref012], [@pone.0144149.ref040]\]. 1,25(OH)~2~D~3~ induces apoptosis in activated B cells and inhibits the generation of plasma cells and memory B cells \[[@pone.0144149.ref041]\]. Isolated peripheral blood mononuclear cells from SLE patients incubated with 1,25(OH)~2~D~3~ significantly reduced cell proliferation, as well as polyclonal and anti-dsDNA immunoglobulin production \[[@pone.0144149.ref042]\]. In sum, the *in vitro* data suggests a potential role of vitamin D in mitigating the pro-inflammatory pathogenic pathways of autoimmune diseases such as SLE.

Vitamin D deficiency is common in patients with SLE. It is estimated that between 8--30% of SLE patients have vitamin D deficiency during the course of the disease \[[@pone.0144149.ref012]\]. As Singapore lies 1° north of the equator and receives 12 hours of sunlight a day throughout the year, this study population provides a unique opportunity to evaluate vitamin D status in the absence of seasonal variation in ultraviolet B (UVB) exposure \[[@pone.0144149.ref043]\]. Although a single 20 min exposure of the summer sun of a fair-skinned individual can help synthesize 20,000 units of vitamin D~3~, 8.2% of SLE patients in this study were deficient in vitamin D despite supplementation \[[@pone.0144149.ref037]\]. This may be due to use of photo-protection, urinary loss of total 25(OH)D, medications and anti-vitamin D antibodies \[[@pone.0144149.ref035], [@pone.0144149.ref044]\]. SLE patients with active disease or cognitive dysfunction may be less inclined to spend time outdoors, as an example of reverse causality. However, most of our patients were in good health at the time of assessment with low SELENA-SELDAI scores. A recent randomized, placebo-controlled trial with vitamin D~3~ failed to diminish the interferon signature in SLE patients with total 25(OH)D levels ≤ 20 ng/mL \[[@pone.0144149.ref036]\]. Nonetheless, a modest improvement of SELENA-SLEDAI in the presence of higher total 25(OH)D levels has been demonstrated in SLE patients with total 25(OH)D levels \< 40 ng/mL in a cohort study \[[@pone.0144149.ref045]\]. The larger sample size of the study by Petri *et al*. might explain why we were unable to find a relationship between 25(OH)D~3~ levels and SELENA-SLEDAI in our study \[[@pone.0144149.ref045]\].

More work is required to address the clinical relevance of and potential relationship between vitamin D deficiency and cognitive dysfunction in SLE patients. T2-weighted white matter hyperintensities localized to the periventricular and subcortical white matter on magnetic resonance imaging (MRI) of the brain have been described in subjects with vitamin D deficiency and SLE-attributed cognitive dysfunction \[[@pone.0144149.ref003], [@pone.0144149.ref046]\]. The clinical relevance of these T2-weighted white matter hyperintensities is related to the disruption of cortico-subcortical white matter tracts that connect brain regions important for subserving cognitive function \[[@pone.0144149.ref046]\]. Newly diagnosed SLE patients with no focal neurological symptoms who underwent ^18^F-fluorodeoxyglucose (^18^FDG) positron emission tomography had increased ^18^FDG uptake in the white matter, indicative of inflammatory activity \[[@pone.0144149.ref047]\]. This suggests that cognitive dysfunction in SLE might result from white matter inflammation as an inciting pathology with subsequent white matter tract damage \[[@pone.0144149.ref003]\]. The capabilities of sophisticated MRI techniques such as diffusion-tensor imaging (DTI) and spectroscopy which detect microstructural and metabolic abnormalities respectively may assist to further the understanding of hypovitaminosis D-related cognitive dysfunction in SLE \[[@pone.0144149.ref048]\]. The positive association with vitamin D levels and the integrity of white fibers using DTI can potentially explain our findings of higher SLICC/ACR Damage Index in SLE patients with lower 25(OH)D~3~ levels \[[@pone.0144149.ref049]\].

The current study has several limitations. First, the study sample was not matched for potential confounders of education and ethnicity. However, more stringent specifications would lead to a smaller sample size, but inclusion of both variables in the multiple regression models for all analyses would partially compensate for this. Second, traditional neuropsychological testing was not performed to look for clinical behavioral correlates of the abnormalities found on ANAM testing. ANAM has been validated for use in SLE to assess cognitive function and demonstrates both good sensitivity (76.2%) and specificity (82.8%) in classifying SLE patients with probable versus no impairment on traditional neuropsychological testing \[[@pone.0144149.ref018], [@pone.0144149.ref050]\]. Although ANAM does not measure complex aspects of memory, language and visuospatial functions, factor analyses have demonstrated that both ANAM and traditional neuropsychological tests measure similar underlying cognitive domains, including processing speed, working memory and resistance to interference \[[@pone.0144149.ref050], [@pone.0144149.ref051]\]. Further, ANAM provides more sensitive assessment of information processing speed and complex attention functions, which are not well assessed with traditional neuropsychological testing \[[@pone.0144149.ref018]\]. More importantly for this study, each ANAM test can be computer scored to yield a summary statistic, the total throughput score (TTS), to assess overall neurocognitive efficiency as a surrogate of overall cognitive impairment (i.e. brain health) of SLE patients \[[@pone.0144149.ref005], [@pone.0144149.ref020]\]. This summary statistic allowed for multiple linear regression for us to identify 25(OH)D~3~ deficiency as an independent negative predictor for TTS. On the other hand, the ACR neuropsychological battery is composed of different instruments assessing domains of simple attention, complex attention, reasoning and/or problem solving, executive functions, memory, visual-spatial processing and psychomotor speed \[[@pone.0144149.ref052]\]. These instruments were developed by different agencies and the scores from different instruments cannot be combined into a single summary statistic. As a result, outputs from traditional neuropsychological testing are not compatible with such analysis. The Cognitive Symptom Inventory (CSI) has been recommended as a screening tool for SLE patients suspected of having cognitive impairment in research and clinical settings; however, later studies indicated that the CSI alone is insufficient to accurately determine the likelihood of significant cognitive impairment \[[@pone.0144149.ref052], [@pone.0144149.ref053]\]. Rather, cognitive complaints reported in the CSI are influenced by the presence of anxiety and depression \[[@pone.0144149.ref053]\]. Lastly, although we did not have baseline levels of 25(OH)D~3~ in our subjects before study entry, a one-time assessment of total 25(OH)D levels has been shown to moderately reflect vitamin D status of individuals over an approximately 5-year period \[[@pone.0144149.ref054]\].

To our knowledge, this study is the first report which addressed the potential relationship between vitamin D levels and cognitive function in SLE patients. The association between 25(OH)D~3~ deficiency and cognitive impairment in SLE is novel and may provide further insights into the pathophysiological impact of vitamin D on cognitive dysfunction. The effects of the VDR likely depend on adequate concentrations of 25(OH)D~3~ as a substrate, which makes vitamin D levels or status a crucial factor in the normal functioning of the nervous and immune systems. Further prospective studies are warranted to clarify if SLE patients with 25(OH)D~3~ deficiency are more likely to experience cognitive dysfunction and whether the correction of 25(OH)D~3~ deficiency with vitamin D~3~ supplementation could improve or even prevent the process of cognitive dysfunction amongst SLE patients.
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